Skip to content

FDA Legal, Regulatory & Compliance Issues, Part 4: Mergers & Acquisitions

October 22, 2026 · 43 min

Show notes

In this fourth and final part of our series in collaboration with Arnall Golden Gregory LLP, Wayne chats with Alan Minsk, Partner, Chair of the Food & Drug practice, and Co-chair of the Life Sciences industry team at AGG; and Brian Teras, Partner in the Corporate & Securities practice at AGG. Together, they discuss current mergers and acquisitions trends and issues for FDA-regulated companies, recent shifts in the M&A environment, the FDA administration's regulatory approach and its effects on corporate transactions, the FDA Transparency Roadmap and its implications for M&A, common mistakes by buyers and sellers when evaluating deals, emerging FDA regulatory developments that could affect M&A activity, and much more.

This episode and the rest of our series do not include the usual Headlines and Resources Links segments.

To subscribe or find out more information about our podcast, visit FDAWatch.net.

Want to be a sponsor, marketing partner, or guest, or provide feedback on the podcast? Email us at [email protected].

Music by Dvir Silver from Pixabay.

All episodes of FDA Watch

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.